Pharmacy

Your Article Summary

See Latest Articles

Biovail Announces Results from ACADIAs Phase III Trial of Pimavanserin in Parkinsons Disease Psychosis
BioVail Corporation, 09/02/09

Biovail Corporation announced top–line results from ACADIA Pharmaceutical Inc.'s first pivotal Phase III trial with pimavanserin in patients with Parkinson's disease psychosis, or PDP. The study did not meet its primary endpoint of antipsychotic efficacy as measured using the Scale for the Assessment of Positive Symptoms, or SAPS. Pimavanserin met the key secondary endpoint of motoric tolerability as measured using the Unified Parkinson’s Disease Rating Scale, or UPDRS.

Today in Drug Trials...keeping you current

Receive free subspecialty "5-minute updates" via email

A phase I dose-escalation and bioavailability study of oral and intravenous formulations of erlotinib (Tarceva, OSI-774) in patients with advanced solid tumors of epithelial origin
Cancer Chemotherapy and Pharmacology, 12/11/09

Data Presented at San Antonio Breast Cancer Symposium Demonstrate Treatment with Denosumab is Superior to the Standard of Care
Amgen, 12/11/09

Phase I Study of Intravenous Vascular Endothelial Growth Factor Trap, Aflibercept, in Patients With Advanced Solid Tumors
Journal of Clinical Oncology, 12/10/09

 See all of Drug Trials

Today in Neuro/Psych pharmacology...keeping you current

Receive free subspecialty "5-minute updates" via email

Natalizumab treatment in multiple sclerosis: Marked decline of chemokines and cytokines in cerebrospinal fluid
Multiple Sclerosis, 12/11/09

Behavioral Dimensions and Acetylcholinesterase Inhibitor-related Effect in Alzheimer Disease Over Time: A Latent Trajectory Modeling
Cognitive and Behavioral Neurology, 12/11/09

Depression in Parkinson's Disease
Canadian Journal of Neurological Sciences, 12/10/09

 See all of Neuro/Psych pharmacology